The trials for adjuvant use of taxanes are large, well designed, and well conducted. Some clinical heterogeneity existed between trials, with variation in choice of control chemotherapy, doses and scheduling of chemotherapy. Post-hoc analyses in a side-by-side comparison of pooled data were performed for a number of subgroups. Information about optimal taxane regimens and efficacy in certain subgroups is not yet available.
Only one trial for neoadjuvant use of taxanes was large enough to detect survival benefits. Future trials and reviews are needed to answer important unanswered questions on neoadjuvant use of taxanes in early breast cancer.
Clinical practice recommendations developed by NBOCC* will be reviewed and revised as required as additional significant evidence becomes available.
* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.